Wiviott, Stephen D <br/><br/>
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.  [electronic resource] 

 -  Circulation  Oct 2008 
 - 1626-36 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/CIRCULATIONAHA.108.791061  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Clopidogrel<br/>Coronary Thrombosis--complications<br/>Diabetes Mellitus, Type 1--complications<br/>Diabetes Mellitus, Type 2--complications<br/>Female<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin--administration & dosage<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--complications<br/>Myocardial Ischemia--complications<br/>Piperazines--administration & dosage<br/>Platelet Aggregation Inhibitors--administration & dosage<br/>Prasugrel Hydrochloride<br/>Thiophenes--administration & dosage<br/>Thrombolytic Therapy--methods<br/>Ticlopidine--administration & dosage<br/>Treatment Outcome